Puma Biotechnology Reports First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Puma Biotechnology (PBYI) PT Lowered to $87 at Stifel
May 10, 2018 5:09 PM EDTStifel lowered its price target on Puma Biotechnology (NASDAQ: PBYI) to $87.00 (from $95.00) while maintaining a Buy rating.
Analyst Alex Schwartz commented, "Yesterday Puma reported 1Q18 numbers that included $66.5 million in revenue and a $24.3 million net loss. Nerlynx revenues of $36.0 million were below our $42.1 million... More
Buy the Puma Biotechnology (PBYI) Dip - Citi
May 10, 2018 12:32 PM EDTCiti analyst Yigal Nochomovitz came out to defend Puma Biotechnology (NASDAQ: PBYI), saying the sell-off is overdone and to buy the dip.
He said the Possible explanations in order of likelihood 1) Lower apparent demand (NRx / new specialty pharmacy pt adds) in April (~230 / 280) vs. March (~300 / 342), 2)... More
